Ann: Appendix 4E , page-2

FY Loss up 95% to -668k, portion of this attributed to increased depreciation charges (+132k) and increased travel and accom costs related to the UK stem cell business.


sales revenue up 5% and increased across the regions:

Australia up 5% (+330k)
NZ up 20% (+73k)
Asia up 15% (+86k)
UK up 89% (+56k)

I'd look at that and for a full years work, doesn't seem to be a huge amount of progress. But I guess we'd need to know how much was new business vs retention.

from the report:
"Management has prepared a cash flow forecast for the 15 months ended September 2013 that supports the ability of the entity to continue as a going concern. These cash flow projections assume a 6.5% increase in sales and an extension of the bank loan facility. The cash flow points to a positive cash position at the send of September 2013. The Directors are presently satisfied that the projected cash flow will be achieved."

Would be nice if this resulted in no further need to dilute existing shareholders, however at the rate of cash burn against current cash held - will definitely be a close call!

Anyone have a look through the report and have any thoughts?